Composite of coronary heart disease death and non-fatal myocardial infarction was less frequent in the CCTA group compared to ...

SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.

Cardiovascular disease is a general term that refers to many different types of heart problems. Heart disease is the No. 1 ...

A new review published in Genes & Diseases highlights macrophage-targeted therapy as a promising frontier in cardiac regeneration and myocardial repair.

The following is a summary of "Low-dose dobutamine stress myocardial contrast echocardiography for evaluating myocardial ...

In patients with acute heart failure, it is unclear how body mass index affects clinical outcomes following acute myocardial infarction.

Roche’s RHHBY member company, Genentech, announced the FDA approval of TNKase (tenecteplase), a thrombolytic or ...

Researchers have observed that female patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) are more likely to ...

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.

For over two decades, a ‘treatment-risk paradox’ has been described in older adults with cardiovascular disease, with ...

The following is a summary of "Impact of sodium-glucose cotransporter‐2 inhibitors in patients with recent versus previous ...